Unitat de Microbiologia, Facultat de Medicina, Universitat Rovira i Virgili, Reus, Spain.
Antimicrob Agents Chemother. 2011 Feb;55(2):676-9. doi: 10.1128/AAC.00736-10. Epub 2010 Nov 29.
Posaconazole (PSC) is an antifungal drug recommended as an alternative for the treatment of invasive aspergillosis in patients who are refractory or intolerant to primary antifungal therapy. We have evaluated the in vitro activity of PSC against 21 strains of the Aspergillus terreus complex using both broth microdilution and disk diffusion (Neo Sensitabs) methods. PSC showed the same high level of activity against all the strains with the two in vitro methods used. We developed a murine model of disseminated infection to evaluate the efficacy of PSC at 5, 10, or 20 mg/kg of body weight twice a day by using 6 different strains chosen randomly. PSC showed good efficacy, especially at 20 mg/kg, as measured by prolonged survival, tissue burden reduction, histopathology, and lowered galactomannan levels. The PSC levels in serum on the fourth day of treatment were higher than the MICs for the strains tested.
泊沙康唑（PSC）是一种抗真菌药物，推荐用于对原发性抗真菌治疗有抗药性或不耐受的侵袭性曲霉菌病患者的治疗。我们使用肉汤微量稀释法和纸片扩散法（Neo Sensitabs）评估了 PSC 对 21 株土曲霉复合体菌株的体外活性。PSC 对两种体外方法检测到的所有菌株均显示出相同的高活性。我们建立了一种播散性感染的小鼠模型，用随机选择的 6 种不同菌株，以 5、10 或 20mg/kg 体重每天两次的剂量评估 PSC 的疗效。PSC 表现出良好的疗效，尤其是在 20mg/kg 剂量下，表现为延长生存时间、减少组织负担、组织病理学和降低半乳甘露聚糖水平。治疗第四天时，血清中的 PSC 水平高于所测试菌株的 MIC。
